Company intelligence / Profile preview

CIT Therapeutics

Cambridge, Massachusetts, United Statescitytx.com ↗

Ownership: Private
Development stage: Other

Overview

The company leverages proprietary engineering of RNAi trigger molecules (siRNAs) and novel delivery ligands to expand RNAi’s reach for therapeutic applications. City is backed by leading investors, led by scientific and industry veterans, and has substantial facilities in Kendall Square, Cambridge, MA. No published clinical results as of August 2025.

Therapeutic areas: Other
Modalities: Small interfering RNA (siRNA)RNA interference (RNAi)Synthetic RNA trigger molecules
Industry: Biotech

Beyond the preview

Go deeper on CIT Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIT Therapeutics.

Explore the full profile